FRNM · Freenome, Inc. Common stock
Perceptive Capital Solutions Corp (FRNM)
What's happening
- FRNM is down 0.57% today, trading at $13.98. — Live quote
- Volume today (26,760) is well below its 3-month average of 874,780. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-09-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Valuation Measures & Ratios
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
Not enough positive evidence under the current rules.
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-10-20; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on FRNM
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|
| Operating income | -$941.3K | -$858.8K | -$856.2K | -$193.2K | -$256.0K | -$196.1K | -$106.6K |
| Net income | -$114.9K | -$51.7K | $144.6K | $754.8K | $678.6K | $981.5K | $102.9K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $85.8M | $93.3M | $92.8M | $92.2M | $91.4M | $90.6M | $89.9M | $89.0M |
| Total liabilities | $7.1M | $6.3M | $5.7M | $4.4M | $3.7M | $3.7M | $3.7M | $3.6M |
| Stockholders' equity | -$6.3M | -$5.7M | -$4.8M | -$3.1M | -$2.3M | -$2.4M | -$2.1M | -$1.9M |
| Total current assets | $742.2K | $649.7K | $907.6K | $1.3M | $1.5M | $1.3M | $1.2M | $1.4M |
| Total current liabilities | $3.6M | $2.9M | $2.3M | $934.6K | $281.2K | $265.6K | $210.8K | $160.0K |
| Accrued liabilities | $3.6M | $2.9M | $2.3M | $934.6K | $281.2K | $265.6K | $210.8K | $160.0K |
| Retained earnings | -$6.3M | -$5.7M | -$4.8M | -$3.1M | -$2.3M | -$2.4M | -$2.1M | -$1.9M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$129.8K | -$297.9K | -$312.9K | -$166.5K | -$147.5K | -$237.7K | -$79.8K | -$77.5K |
| Investing cash flow | $8.2M | $0 | $0 | $0 | $300.0K | $300.0K | $0 | $0 |
| Financing cash flow | -$8.2M | — | $0 | $0 | $0 | — | $0 | $0 |
| Share-based compensation | $0 | — | — | — | — | — | — | — |
| Purchases of investments | — | — | $0 | $0 | $0 | — | $0 | $0 |
Income statement
| Line item | Dec '25 |
|---|---|
| Operating income | -$3.0M |
| Net income | $837.5K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Mar '24 |
|---|---|---|---|
| Total assets | $92.8M | $89.9M | — |
| Total liabilities | $5.7M | $3.7M | — |
| Stockholders' equity | -$4.8M | -$2.1M | $0 |
| Total current assets | $907.6K | $1.2M | — |
| Total current liabilities | $2.3M | $210.8K | — |
| Accrued liabilities | $2.3M | $210.8K | — |
| Retained earnings | -$4.8M | -$2.1M | — |
Cash flow
| Line item | Dec '25 |
|---|---|
| Operating cash flow | -$864.7K |
| Investing cash flow | $600.0K |
| Financing cash flow | $0 |
| Purchases of investments | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding FRNM as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:14 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-20 | 8-K | 2026-10-20 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-27 | 8-K | 2026-07-27 | View on SEC.gov → |
| 2026-07-24 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-24 | 8-K | 2026-07-20 | View on SEC.gov → |
| 2026-07-23 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-22 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-22 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-22 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-22 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-22 | 4 | 2026-07-20 | View on SEC.gov → |
Recent news
Headlines about FRNM (Freenome, Inc. Common stock). Links open the publisher — we don’t host full articles.
-
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
Yahoo Finance · 2026-10-20 -
FRNM 8-K & SEC Filings
Yahoo Finance · 2026-10-20 -
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
Yahoo Finance · 2026-10-15 -
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
Yahoo Finance · 2026-10-11 -
Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition
Seeking Alpha · 2026-09-22 -
Freenome GAAP EPS of -$2.59
Seeking Alpha · 2026-08-14 -
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
Yahoo Finance · 2026-08-12 -
Freenome (FRNM) Climbed, But What Is Driving Attention Now?
Yahoo Finance · 2026-08-11
No headlines in this category right now — try “All”.